ReviewFrontiers in molecular biosciences2020
Current State of Target Treatment in BRAF Mutated Melanoma.
Review in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.Dermatology and therapy · 2026Article
- Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells.International journal of molecular sciences · 2026Article
- Vertebral metastatic disease: A paradigm shift.Neuro-oncology advances · 2026Review
- Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAFInternational journal of molecular sciences · 2026Article
- A review of deep learning approaches for drug synergy prediction in cancer.npj drug discovery · 2025Review
- Non-coding RNA profiling in BRAFScientific data · 2025Article
- Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Article
- Current Treatment Paradigms for Advanced Melanoma with Brain Metastases.International journal of molecular sciences · 2025Review
- Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells.International journal of molecular sciences · 2025Article
- Novel 5-Oxopyrrolidine-3-carbohydrazides as Potent Protein Kinase Inhibitors: Synthesis, Anticancer Evaluation, and Molecular Modeling.International journal of molecular sciences · 2025Article
- Xanthohumol Sensitizes Melanoma Cells to Vemurafenib by Lowering Membrane Cholesterol and Increasing Membrane Fluidity.International journal of molecular sciences · 2025Article
- Overview of Molecular Prognostication for Common Solid Tumor Histologies - What the Surgeon Should Know.Global spine journal · 2025Article
- Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Advancements and Challenges in Personalized Therapy forJournal of clinical medicine · 2024Review
- Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma.Nature cell biology · 2024Article
- New insights into the anti-inflammatory and anti-melanoma mechanisms of action of azelaic acid and other Fusarium solani metabolites via in vitro and in silico studies.Scientific reports · 2024Article
- Hallmarks of cancer resistance.iScience · 2024Review
- Redefining cancer research for therapeutic breakthroughs.British journal of cancer · 2024Review
- Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review).Experimental and therapeutic medicine · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incidence of melanoma has been constantly growing during the last decades. Although most of the new diagnoses are represented by thin melanomas, the number of melanoma-related deaths in 2018 was 60,712 worldwide (Global Cancer Observatory, 2019). Until 2011, no systemic therapy showed to improve survival in patients with advanced or metastatic melanoma. At that time, standard of care was chemotherapy, with very limited results. The identification of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.